文献速递肾移植

肾移植后淋巴增殖性疾病综述

Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
PubMed 文献 · Am J Kidney Dis · 2021-03-25

肾移植受者10年内PTLD风险为匹配非移植人群的12倍,且因肾移植数量多,肾移植后PTLD患者数超过其他器官移植后PTLD患者。EB病毒感染是最重要风险因素之一,但当代系列中40%的PTLD与EB病毒无关。免疫抑制总体水平似乎是实体器官移植受者PTLD增加的最重要驱动因素。降低免疫抑制被普遍接受用于预防和治疗PTLD;

要点

  • 肾移植受者10年PTLD风险为匹配非移植人群的12倍。
  • EB病毒感染是重要风险因素,但当代40%PTLD与EB病毒无关。
  • 降低免疫抑制是预防和治疗PTLD的常用策略。

核心结论

  • 肾移植受者PTLD风险显著高于匹配非移植人群,免疫抑制总体水平是主要驱动因素,降低免疫抑制被普遍接受用于预防和治疗,利妥昔单抗改变了治疗格局。

研究设计与样本

  • 综述,聚焦肾移植受者PTLD的最新流行病学、表现、风险因素和管理数据。

主要发现

  • 肾移植受者10年内PTLD风险为匹配非移植人群的12倍。
  • 肾移植后PTLD患者数超过其他器官移植后PTLD患者。
  • EB病毒感染是最重要风险因素之一,但当代系列中40%的PTLD与EB病毒无关。
  • 免疫抑制总体水平似乎是实体器官移植受者PTLD增加的最重要驱动因素。

关键数值与推荐

  • 肾移植受者10年PTLD风险为匹配非移植人群的12倍。
  • 当代系列中40%的PTLD与EB病毒无关。

临床怎么用

  • 降低免疫抑制被普遍接受用于预防和治疗PTLD。
  • 利妥昔单抗已改变PTLD治疗格局,化疗(如环磷酰胺-多柔比星-长春新碱-泼尼松)曾是基石。
  • PET-CT用于分期和反应监测,更统一的治疗方案和支持治疗改善可改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Posttransplant lymphoproliferative disorder (PTLD) is one of the most feared complications following kidney transplantation. Over a 10-year period, the risk of PTLD in kidney transplant recipients (KTRs) is 12-fold higher than in a matched nontransplanted population. Given the number of kidney transplants performed, KTRs who experience PTLD outnumber other organ transplant recipients who experience PTLD. Epstein-Barr virus infection is one of the most important risk factors for PTLD, even though 40% of PTLD cases in contemporary series are not Epstein-Barr virus-associated. The overall level of immunosuppression seems to be the most important driver of the increased occurrence of PTLD in solid organ transplant recipients. Reduction in immunosuppression is commonly accepted to prevent and treat PTLD. Although the cornerstone of PTLD treatment had been chemotherapy (typically cyclophosphamide-doxorubicin-vincristinr-prednisone), the availability of rituximab has changed the treatment landscape in the past 2 decades. The outcome of PTLD in KTRs has clearly improved as a result of the introduction of more uniform treatment protocols, improved supportive care, and increased awareness and use of positron emission tomography combined with computed tomography in staging and response monitoring. In this review, we will focus on the most recent data on epidemiology, presentation, risk factors, and management of PTLD in KTRs.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Sprangers B, Riella LV, Dierickx D, et al. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. Am J Kidney Dis. 2021. PMID: 33774079. doi:10.1053/j.ajkd.2021.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。